Ketamine in treatment resistant major depression (TRD)

This double-blind, placebo-controlled therapeutic exploratory trial (n=80) investigates the effectiveness of a single intravenous application of ketamine at subanaesthetic doses in patients with treatment-resistant major depression (TRD).

The study, conducted by the Medical Faculty, University Magdeburg, Germany, aims to assess improvement in Hamilton Depression Rating Scale (HAMD) scores as the primary endpoint. Secondary objectives include exploring predictive biomarkers for treatment response and monitoring changes in glutamine concentrations using MR spectroscopy.

The trial, with a duration of 18 months, has been authorised by the German Competent Authority and received a favourable Ethics Committee opinion on January 25, 2012. The trial concluded on April 22, 2016.

Trial Details

This completed therapeutic exploratory trial (n=80) examined the efficacy of a single intravenous ketamine dose in treating treatment-resistant major depression. Conducted in Germany, the study assessed improvement in Hamilton Depression Rating Scale (HAMD) scores, explored predictive biomarkers, and monitored glutamine concentrations. Authorized by the German Competent Authority and with Ethics Committee approval on January 25, 2012, the trial concluded on April 22, 2016.

Trial Number 2010-023414-31

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.